Skip to main content
Erschienen in: Archives of Dermatological Research 3/2023

23.07.2022 | Original Paper

Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study

verfasst von: Khalaf Kridin, Kailyn Valido, Jeffrey M. Cohen, Arnon D. Cohen

Erschienen in: Archives of Dermatological Research | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have identified an association between myocardial infarction (MI), cerebrovascular accident (CVA), and peripheral vascular disease (PVD) in patients with hidradenitis suppurativa (HS). To evaluate the risk and prognostic outcomes of MI, CVA, and PVD in patients with HS. A population-based retrospective cohort study using the computerized database of Clalit Health Services (CHS), the largest managed care organization in Israel, was conducted to compare the incidence of MI, CVA, and PVD among patients with HS (N = 6779) with age-, sex- and ethnicity-matched control subjects (N = 33,260). Adjusted hazard ratios (HRs) were estimated by multivariate Cox regression analysis. The overall incidence rates of MI, CVA, and PVD were estimated at 2.9 (2.3–3.4), 1.3 (0.9–1.7), and 0.8 (0.6–1.1) per 1000 person-year, respectively. Patients with HS were at an increased risk of developing MI (fully-adjusted HR 1.33; 95% CI 1.04–1.68; P = 0.021), but the risk of CVA (fully-adjusted HR 0.82; 95% CI 0.59–1.14; P = 0.245) and PVD (fully-adjusted HR 1.22; 95% CI 0.80–1.87; P = 0.355) was comparable relative to controls. Compared to other patients with HS, increased risk of all-cause mortality was observed among patients with HS and comorbid MI (HR 12.56; 95% CI 7.59–20.80; P < 0.001), CVA (HR 13.33; 95% CI 7.29–24.37; P < 0.001), and PVD (HR 7.11; 95% CI 2.61–19.32; P < 0.001). Patients with HS are at an increased risk of MI, but not CVA and PVD. Awareness of these epidemiological findings is of importance for clinicians managing patients with HS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644CrossRefPubMed Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644CrossRefPubMed
2.
Zurück zum Zitat Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol 11(10):17–23PubMedPubMedCentral Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol 11(10):17–23PubMedPubMedCentral
3.
Zurück zum Zitat Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032CrossRefPubMed Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032CrossRefPubMed
4.
Zurück zum Zitat Ingram JR (2020) The epidemiology of hidradenitis suppurativa. Br J Dermatol 183(6):990–998CrossRefPubMed Ingram JR (2020) The epidemiology of hidradenitis suppurativa. Br J Dermatol 183(6):990–998CrossRefPubMed
5.
Zurück zum Zitat Ballard K, Shuman VL (2021) Hidradenitis suppurativa. In: StatPearls. Treasure Island, FL. Ballard K, Shuman VL (2021) Hidradenitis suppurativa. In: StatPearls. Treasure Island, FL.
6.
Zurück zum Zitat Nguyen TV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35(1):50–61CrossRefPubMed Nguyen TV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35(1):50–61CrossRefPubMed
7.
Zurück zum Zitat Lyons AB et al (2020) Emerging medical treatments for hidradenitis suppurativa. J Am Acad Dermatol 83(2):554–562CrossRefPubMed Lyons AB et al (2020) Emerging medical treatments for hidradenitis suppurativa. J Am Acad Dermatol 83(2):554–562CrossRefPubMed
8.
Zurück zum Zitat Casseres RG et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524–1526CrossRefPubMed Casseres RG et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524–1526CrossRefPubMed
9.
Zurück zum Zitat Prussick L et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609–611CrossRefPubMed Prussick L et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609–611CrossRefPubMed
10.
Zurück zum Zitat Rosales Santillan M et al (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 20(6):621–633CrossRefPubMed Rosales Santillan M et al (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 20(6):621–633CrossRefPubMed
11.
Zurück zum Zitat Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434CrossRefPubMed Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434CrossRefPubMed
12.
Zurück zum Zitat Miller IM, McAndrew RJ, Hamzavi I (2016) Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin 34(1):7–16CrossRefPubMed Miller IM, McAndrew RJ, Hamzavi I (2016) Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin 34(1):7–16CrossRefPubMed
13.
14.
Zurück zum Zitat Keary E, Hevey D, Tobin AM (2020) A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol 182(2):342–347CrossRefPubMed Keary E, Hevey D, Tobin AM (2020) A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol 182(2):342–347CrossRefPubMed
15.
Zurück zum Zitat Shavit E et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(2):371–376CrossRefPubMed Shavit E et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(2):371–376CrossRefPubMed
16.
17.
Zurück zum Zitat Miller IM et al (2018) Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol 178(3):790–791CrossRefPubMed Miller IM et al (2018) Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol 178(3):790–791CrossRefPubMed
18.
Zurück zum Zitat Cohen AD et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149(4):204–209PubMed Cohen AD et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149(4):204–209PubMed
19.
Zurück zum Zitat Tzellos T et al (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142–1155CrossRefPubMed Tzellos T et al (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142–1155CrossRefPubMed
20.
Zurück zum Zitat Pascual JC et al (2017) Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31(7):1229–1238CrossRefPubMed Pascual JC et al (2017) Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31(7):1229–1238CrossRefPubMed
21.
Zurück zum Zitat Jimenez-Gallo D et al (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401CrossRefPubMedPubMedCentral Jimenez-Gallo D et al (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 79(2):345–352CrossRefPubMed Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 79(2):345–352CrossRefPubMed
23.
Zurück zum Zitat Mora-Ruiz MD et al (2019) Role of interleukin-17 in acute myocardial infarction. Mol Immunol 107:71–78CrossRefPubMed Mora-Ruiz MD et al (2019) Role of interleukin-17 in acute myocardial infarction. Mol Immunol 107:71–78CrossRefPubMed
24.
Zurück zum Zitat Zhang L et al (2019) IL-17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPKalpha/p38MAPK/ERK1/2 signal pathway in mice. Mol Immunol 105:240–250CrossRefPubMed Zhang L et al (2019) IL-17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPKalpha/p38MAPK/ERK1/2 signal pathway in mice. Mol Immunol 105:240–250CrossRefPubMed
25.
Zurück zum Zitat Reddy S et al (2020) Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol 156(1):65–71CrossRefPubMed Reddy S et al (2020) Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol 156(1):65–71CrossRefPubMed
26.
Zurück zum Zitat Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefPubMed Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434CrossRefPubMed
27.
Zurück zum Zitat Reddy S, Strunk A, Garg A (2019) All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol 81(4):937–942CrossRefPubMed Reddy S, Strunk A, Garg A (2019) All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol 81(4):937–942CrossRefPubMed
Metadaten
Titel
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study
verfasst von
Khalaf Kridin
Kailyn Valido
Jeffrey M. Cohen
Arnon D. Cohen
Publikationsdatum
23.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 3/2023
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-022-02369-5

Weitere Artikel der Ausgabe 3/2023

Archives of Dermatological Research 3/2023 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.